A5028773223- Heart Failure Treatment and Management
- Diabetes Treatment and Management
- Cardiovascular Function and Risk Factors
- Influenza Virus Research Studies
- Potassium and Related Disorders
- Diabetes Management and Research
- Mechanical Circulatory Support Devices
- Vaccine Coverage and Hesitancy
- Pancreatic function and diabetes
- Blood Pressure and Hypertension Studies
- Cardiac Imaging and Diagnostics
- Cardiac pacing and defibrillation studies
- Electrolyte and hormonal disorders
- Respiratory viral infections research
- Cardiac Valve Diseases and Treatments
- Dialysis and Renal Disease Management
- Mobile Health and mHealth Applications
- Hormonal Regulation and Hypertension
- Transplantation: Methods and Outcomes
- Cardiac Arrhythmias and Treatments
- Cardiac electrophysiology and arrhythmias
- Cholesterol and Lipid Metabolism
- Organ and Tissue Transplantation Research
- Sodium Intake and Health
- Smoking Behavior and Cessation
Brigham and Women's Hospital
2020-2025
Harvard University
2022-2025
Massachusetts General Hospital
2025
Copenhagen University Hospital
2024
Mass General Brigham
2023
University of Calgary
2019
Libin Cardiovascular Institute of Alberta
2019
Calgary Laboratory Services
2014-2018
University of British Columbia
2010-2016
Providence Health Care
2016
Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with mildly preserved ejection fraction. In this study, safety and efficacy dapagliflozin according to background diuretic therapy influence on longitudinal use were evaluated.
SGLT-2 inhibitors are guideline-recommended in the management of heart failure(HF). While these therapies can be initiated even patients with comorbid CKD, some may face deterioration kidney function over time. To examine safety and efficacy continuing HF when eGFR falls below thresholds for initiation. Associations between a 25 ml/min/1.73m2 , outcomes, treatment dapagliflozin were evaluated time-updated Cox proportional hazards models participant-level pooled analysis DAPA-HF DELIVER....
Hospitalization is recognized as a sentinel event in the disease trajectory of patients with heart failure (HF), but not all experiencing clinical decompensation are ultimately hospitalized. Outpatient intensification diuretics common response to symptoms worsening HF, yet its prognostic and relevance, specifically for HF mildly reduced or preserved ejection fraction, uncertain.
Some patients with heart failure may experience transient changes in kidney function upon transition to sacubitril/valsartan. Whether such portend adverse outcomes or influence long-term treatment benefits sacubitril/valsartan continuation is unknown.This investigation aimed evaluate the association between occurrence of moderate estimated glomerular filtration rate (eGFR) decline (>15%) after initial exposure and subsequent cardiovascular its PARADIGM-HF PARAGON-HF.In sequential run-in...
Despite strong worldwide guideline recommendations, influenza vaccination rates remain suboptimal among young and middle-aged patients with chronic diseases. Effective scalable strategies to increase are needed.
Aims Patients recently hospitalized for heart failure (HF) often have unstable haemodynamics and experience worsening renal failure, are at elevated risk recurrent HF events. In DELIVER, dapagliflozin reduced events or cardiovascular death including among patients who were hospitalized. Methods results We examined the effects of versus placebo on estimated glomerular filtration rate (eGFR) slope (acute chronic), 1‐month change in systolic blood pressure, occurrence serious hypovolaemic...
Yearly influenza vaccination is strongly recommended for older adults and patients with chronic diseases including cardiovascular disease (CVD); however, rates remain suboptimal, particularly among younger patients. Electronic letters incorporating behavioral nudges are highly scalable public health interventions which can potentially increase vaccination, but further research needed to determine the most effective strategies assess effectiveness across different populations. The purpose of...
Worsening renal function may impact long-term outcomes in heart failure (HF). However, little is known about the longitudinal trajectories relation to HF hospitalization or how this high-risk clinical event impacts outcomes.In PARAGON-HF, we evaluated association between recency of prior (occurring pre-randomization) and subsequent first composite outcome: (i) time ≥50% decline estimated glomerular filtration rate (eGFR); (ii) development end-stage disease; (iii) death attributable causes. A...
Importance Worsening heart failure (HF) is commonly managed in the outpatient setting with adjustments oral diuretic therapy. The effect of nonsteroidal mineralocorticoid receptor antagonist finerenone on worsening HF events patients mildly reduced or preserved ejection fraction unknown. Objective To evaluate requiring intensification among fraction. Design, Setting, and Participants This a secondary analysis Finerenone Trial to Investigate Efficacy Safety Superior Placebo Patients With...
Importance Influenza vaccination in patients with acute myocardial infarction (AMI) reduces major adverse cardiac events and is strongly recommended clinical practice guidelines. Effective strategies to improve are needed these high-risk patients. Objective To evaluate whether electronically delivered behavioral nudges influenza vaccine uptake AMI across 3 nationwide implementation randomized trials (RCTs). Design, Setting, Participants Nationwide Utilization of Danish Government Electronic...
Background We examined temporal trends, timing, and frequency, as well adverse neonatal maternal outcomes occurring in the first year postpartum among women experiencing syncope during pregnancy. Methods Results This was a retrospective study of pregnancies between January 1, 2005, December 31, 2014, province Alberta, Canada. Of 481 930 pregnancies, 4667 had an episode syncope. Poisson regression analysis found 5% increase/year (rate ratio, 1.05; 95% CI, 1.04-1.06) age-adjusted incidence...
Dapagliflozin resulted in significant and sustained reductions first recurrent heart failure (HF) hospitalizations among patients with HF across the spectrum of ejection fraction. How treatment dapagliflozin differentially impacts hospitalization for varying complexity is not well studied.In DELIVER DAPA-HF trials, we examined effects on adjudicated hospital length stay (LOS). requiring intensive care unit stay, intravenous vasoactive therapies, invasive/non-invasive ventilation, mechanical...